Janssen to acquire oncolytic virus company BeneVir

The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) is acquiring oncolytic virus company BeneVir Biopharm Inc. (Rockville,

Read the full 198 word article

User Sign In